🏛️ Verified NIH Record • Updated 2026-07-13
Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) (NCT02736656)
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of SPN-812 for the Treatment of Pediatric Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Supernus Pharmaceuticals, Inc.
🩺 Plain-English Summary (8th-Grade Level)
Open label extension, long-term multicenter study of safety and efficacy of SPN-812 in pediatric ADHD patients
Who can join: Review the eligibility criteria below.
Location: Woodland International Research Group — Little Rock, Arkansas
Age range: 4 Years to 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (16 Sites)
- Woodland International Research Group — Little Rock, Arkansas
- Alliance for Wellness dba Alliance for Research — Long Beach, California
- MCB Clinical Research Centers, LLC — Colorado Springs, Colorado
- Meridien Research at Florida Clinical Research Center — Bradenton, Florida
- Sarkis Clinical Trials — Gainesville, Florida
- Indago Research & Health Center, Inc. — Hialeah, Florida
- Florida Clinical Research Center, LLC. — Maitland, Florida
- Florida Clinical Research Center, LLC — Maitland, Florida
- IPS Research — Oklahoma City, Oklahoma
- Paradigm Research Professionals — Oklahoma City, Oklahoma
- Clinical Neuroscience Solutions, Inc. — Memphis, Tennessee
- CNS Healthcare — Memphis, Tennessee
- Bayou City Research Corporation — Houston, Texas
- Road Runner Research — San Antonio, Texas
- Ericksen Research & Development — Clinton, Utah
- Northwest Clinical Trials — Bellevue, Washington
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Attention-Deficit/Hyperactivity Disorder
- An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening — New York, New York
- A Pilot Study of a Remote ADHD Monitoring Program — Jackson, Mississippi
- The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder — Fayetteville, Arkansas
- Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD — Saraland, Alabama
Explore by condition: All Attention-Deficit/Hyperactivity Disorder clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.